Log In
Print
BCIQ
Print
Print this Print this
 

HGT-DEB001

  Manage Alerts
Collapse Summary General Information
Company Shire plc
DescriptionIntravenous formulation of recombinant human collagen type VII (COL7A1)
Molecular Target Collagen type VII (COL7A1)
Mechanism of Action 
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentPreclinical
Standard Indication Dermatology (unspecified)
Indication DetailsTreat dystrophic epidermolysis bullosa (DEB)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$324.3M

$49.3M

$275.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today